Form 4: Intellia Therapeutics Director Receives Equity Grant

Director Fred E. Cohen was granted 9,200 restricted stock units and 13,300 stock options by Intellia Therapeutics.

Summary

• Director Fred E. Cohen received a grant of 9,200 restricted stock units (RSUs) on June 9, 2026.
• The director was also granted 13,300 stock options with an exercise price of $12.89 per share.
• Following these transactions, the director's total beneficial ownership of common stock increased to 216,653 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard retention and incentive structure for board members.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Market volatility affecting the value of equity-based compensation.
• Potential for future dilution if additional equity grants are issued to board members or employees.

Future Outlook

The stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term alignment between leadership and corporate performance.

Comparison to Industry Standards

• Equity compensation for directors is consistent with standard corporate governance practices for mid-cap biotech firms.
• Vesting schedules tied to annual meetings are common industry practice for non-employee directors.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of stock options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, Equity Compensation, Biotech